For example, BRCA1 promoter methylation indicates PARPi resistance of triple-negative breast cancer cells, which makes germline BRCA1 mutations the most reliable biomarkers in predicting tumor response to the PARPi-based therapies [126]. The gene discussed is BRCA1; the disease is triple-negative breast carcinoma.